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The quest for an infectious agent that may account for cases of Hodgkin’s disease (HD) especially in young adults has proven vain
until lately. We have recently reported findings that suggested the presence of measles virus (MV) antigens and MV RNA in the
tissues of patients with HD. Support for an association between MV and HD has been provided by recent epidemiological findings
relating the occurrence of HD to exposure to measles in pregnancy and the perinatal period. We now present further evidence of
this putative association based on immunohistochemical, reverse transcriptase–polymerase chain reaction (RT–PCR) and in situ
hybridisation studies (ISH) on HD tissues. Biopsies from 82 (54.3%) of our cohort of 154 patients showed a positive immunostain
with at least two of the anti-measles antibodies used. Latent membrane protein-1 immunostaining for Epstein–Barr virus was positive
in 46 (31.1%) of the patients examined. Reverse transcriptase–PCR and ISH for measles RNA were positive in seven and 10 of 28
patients, respectively. Preliminary clinicopathological associations between MV and HD are noted in this study, but no causal
relationship can be claimed at this stage.
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An association between Hodgkin’s disease (HD) and infection with
Epstein–Barr virus (EBV) is now well established on the basis of
immunohistochemical (IHC) and in situ hybridisation (ISH)
studies, and causal implications of this association have been
inferred (Knecht et al, 2001; Niedobitek et al, 2001; Jarrett, 2002).
Young adult HD patients from a high socioeconomic environment
do not, however, usually have an EBV-associated disease
(Alexander et al, 2000), although epidemiological evidence
suggests that this age group is the one whose HD is most expected
to be related to late exposure to a common infectious agent
(Gutensohn and Cole, 1981; Glaser, 1990; Westergaard et al, 1997;
Sleckman et al, 1998; Glaser et al, 2002). Evidence of delayed
exposure to EBV is present in only a minority of these young adult
HD patients (Jarrett, 2002). The suggestion that EBV-negative
cases of HD had previously been EBV positive (the hit-and-run
hypothesis) or that a defective EBV genome is integrated in the
chromosomal DNA of EBV-negative tumour cells in HD has not
been confirmed (Delecluse et al, 1997; Brousset, 2002; Gallagher
et al, 2003).
Attempts to demonstrate other infectious agents, including
CMV, HHV-6, -7 and -8, polyoma JC virus, SV40, lympho-
tropic papova virus, HTLV-1 and -2 and human retrovirus 5 in
HD patients, have failed (reviewed in Torreli et al, 1991;
Armstrong et al, 1998; Berneman et al, 1998; Cozen et al, 1998;
Jarrett and MacKenzie, 1999; Schmidt et al, 2000; Gallagher et al,
2002).
We have previously suggested that measles virus (MV) may be
associated with HD (Benharroch et al, 2001; Gopas et al, 2001;
Benharroch et al, 2003). This lymphotropic virus also shows
tropism to the respiratory tract, which may explain the frequent
involvement of cervical and mediastinal lymph nodes in HD.
Following the introduction of vaccination against MV, measles
may appear at an older age than expected (Veit et al, 1991; Desai
et al, 2002). This may represent late exposure to a common
infectious agent and account for the constant incidence of HD, at
least in some countries, in the postmeasles vaccination era. In our
original studies, we found an apparent epidemiologic association
between exposure to outbreaks of measles in girls aged 10 and 16
years and an increased risk of HD in these patients in young
adulthood (Gopas et al, 2001). We also described IHC evidence for
the presence of MV antigens in 60.3% of HD lymph nodes
examined. Our cohort was later expanded, and expression of MV
antigens was found in 105 (73.4%) of HD patients. We also
demonstrated MV RNA sequences in two of 19 biopsies from our
HD patients (Benharroch et al, 2003).
In the present study, we report further IHC, reverse transcrip-
tase–polymerase chain reaction (RT–PCR) and ISH evidence for
the putative association between MV and HD. We also describe
certain preliminary clinical associations with the expression of MV
and EBV in the tissues of HD patients.
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The study was performed on a cohort of 154 patients with classic
HD diagnosed in the years 1975–2000 at the Soroka University
Medical Center in Beer-Sheva, from whom tissues were available
for investigation. This is an expanded cohort of the patients
described in our preliminary studies (Benharroch et al, 2003). Only
primary (pretreatment) biopsies in which the diagnosis and
histological type were confirmed by two haematopathologists
(DB and MS) were considered. Clinical data and follow-up data
were retrieved from the files of the patients or, when these were not
available, were obtained from the Israel Population Registry by
linkage.
Immunohistochemistry
Immunohistochemical studies were performed on paraffin-em-
bedded tissues using the avidin–biotin peroxidase complex
method with the Vectastain kit of Vector Laboratories (Burlin-
game, CA, USA), as described previously (Benharroch et al, 1995).
Latent membrane protein-1 (LMP1) antibody for the EBV antigen
from Dako (Glostrup, Denmark) was used. The anti-MV antibodies
employed (anti-nucleoprotein (NP)-MV, anti-haemagglutinin
(HA)-MV, anti-matrix (M)-MV and anti-phosphoprotein (P)-
MV) were purchased from Chemicon International Inc. (Temecula,
CA, USA). The last two were studied in isolated cases only. In
addition, anti-NP (H14; L39/22; L39/61) and anti-HA (K83; L77)
antibodies were made available to one of us (BR) (H14 from Birrer
et al (1981) and the others from Schneider-Schaulies et al (1992)).
The specificity of these anti-NP-MV antibodies had been
established by Western blotting.
The IHC stains were considered positive if 10% or more of the
Hodgkin–Reed–Sternberg (HRS) cells were stained. In order to
increase the stringency of the assay, a case was considered positive
for MV, if at least two of the NP and/or HA antibodies mentioned
above were positive. A murine neuroblastoma cell line perma-
nently infected by MV (Gopas et al, 1992) was used as a positive
control and the same cell line, but without infection with MV, was
used as a negative control. These cell lines were also used as
controls for the RT–PCR and ISH studies. In all, 25 sections from
cases of non-Hodgkin’s lymphomas (NHL) were also examined by
IHC.
RT–PCR analysis
Total RNA was extracted from frozen lymph node samples from a
subset of our HD patients, in whom frozen tissue from a primary
biopsy was available. For this purpose, we used EZ-RNA Total
RNA Isolation kit (Biological Industries Co., Beit Haemek, Israel)
according to the manufacturer’s instructions. In all, 40U of RNA-
guard (Promega, Madison, WI, USA) were added to each sample.
One-step RT–PCR was carried out with Ready To Got RT-PCR
beads (Amersham Pharmacia Biotech Europe GmbH, Freiburg,
Germany). A measure of 3ml of RNA (2–6mg) was used for each
reaction. The primers used in this study are shown in Table 1.
Nested PCR was performed using SUPER-NOVA DNA polymerase
(Roche Molecular Biochemicals, Mannheim, Germany).
RNA was also extracted from several paraffin-embedded tissue
sections from HD patients, using the Paraffin Block RNA Isolation
kit (Ambion Inc., The RNA Company, Austin TX, USA) and RT–
PCR followed by nested PCR was performed with 10ml of extracted
RNA as described above.
In addition to the neuroblastoma cell lines mentioned above,
seven cases of NHL and a case of HD shown to be negative for MV
by IHC were included as controls. The quality of the RNA
preparations was tested by amplification of transcripts of the
housekeeping genes, b-actin and protein phosphatase 2C b
(pp2Cb).
To confirm our RT–PCR findings, the cDNA products of the
nested PCR were blotted to GeneScreen (NEN Research Products,
Boston, MA, USA) and hybridised to either an NP-MV probe
(CAATCCCTGGAGATTCCTCA) or to an HA-MV probe
(GCTGGAAGCTGACACCTTTC), labelled with [g-
32P]ATP (Amer-
sham).
ISH on paraffin sections
For the preparation of digoxigenin (DIG)-labelled antisense and
sense probes to MV-specific mRNAs, the plasmids containing NP-
MV encompassing positions 105–586 and those containing HA-
MV encompassing positions 8147–8482 in PGEM-T Easy Vectors
(Promega) were linearised with SalIo rSacII. In vitro transcription
was performed with the DIG-RNA Labelling kit, using SP6 for NP
antisense and HA sense probes and T7 for NP sense and HA
antisense DIG-labelled probes. The quality of the probes was
determined by dot blotting using a DIG-DNA detection kit (Roche
Molecular Biochemicals) according to the manufacturer’s instruc-
tions with minor modifications.
In situ hybridisation was carried out according to the method of
Ogata et al (1997) with certain modifications. Paraffin sections
were deparaffinised, rehydrated and treated by microwave in the
presence of 10mM MgCl2 buffer (pH 6) for 5min at 750W.
Sections were allowed to cool for 20min, and then digested with
20mgml
 1 proteinase K for 10min at 371C. They were then fixed in
4% paraformaldehyde in 0.1 M phosphate buffer, acetylated,
dehydrated and air-dried. Hybridisation was performed overnight
at 501C with DIG-labelled RNA in hybridisation buffer containing
50% formamide, 10mM Tris-HCl (pH 7.6), 200mgml
 1 tRNA,
1 Denhardt’s solution, 10% dextran sulphate, 600mM NaCl,
Table 1 Primers used for nested RT–PCR
Gene region amplified Primer symbol Primer sequence Location in region Product size
HA HM3 (upstream/outer) CAGTCAGTAATGATCTCAGC 8106–8125 596
H6 (downstream/outer) CTTGAATCTCGGTATCCACTCCAAT 8677–8701
H7 (upstream/inner) GAGCTCAAACTCGCAGCCCTTTGTC 8147–8171 336
H4A (downstream/inner) ATCCTTCAATGGTGCCCACTCGGGA 8458–8482
NP NPM2 (upstream/outer) GGGATATCCGAGATGGCCACACTTTTAAGG 96–125 529
NPMRT (downstream/outer) GGGCTAGGATGGATCCCAGAATCATGTTG 625–597
NPM3 (upstream/inner) GGGTCTTGCACTTCAATATCTGAG 105–127 482
NPM4 (downstream/inner) GGGTCTTGCACTTCAATATCTGAG 586–563
pp2Cb 8.861F GGG,AAG,TCG,AGA,TAA,CAT,GAG 16151–16171 290
9.576R CCCATCACTTTCTCTATGTG 25480–25460
RT–PCR¼reverse transcriptase–polymerase chain reaction; HA¼haemagglutinin; NP¼nucleoprotein; pp2Cb¼protein phosphatase 2Cb.
Measles virus in Hodgkin’s disease
D Benharroch et al
573
British Journal of Cancer (2004) 91(3), 572–579 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y0.25% SDS and 1mM EDTA, pH 8.0. Hybridised DIG-labelled
probes were detected using the DIG-Nucleic Acid Detection kit
(Roche Molecular Biochemicals), following blocking with 1.5% of
the blocking reagent included in the kit. The colour reaction was
stopped with 10mM Tris-HCl (pH 7.6) and 1mM EDTA. Sections
were then fixed in 4% paraformaldehyde in phosphate-buffered
saline and stained with haematoxylin. In addition to the
neuroblastoma cell lines used as positive and negative controls,
HD cases negative for MV by IHC and NHLs served as controls.
Comparison between IHC, RT–PCR and ISH
This was performed on a sample of cases. For this comparison,
IHC positivity to a single NP-MV or HA-MV antibody was
considered sufficient.
Clinicopathological correlations
A clinicopathological study on MV and EBV expression in HD is
under way. Some of the preliminary findings are presented here,
but the complete study will be described in a separate publication.
For contingency table analysis, the w
2 or Fisher’s exact test was
used, as appropriate.
RESULTS
Biopsies were obtained from 90 male and 64 female patients with
untreated classical HD. Their ages ranged from 4 to 86 (mean
35.6717.2 and median 33.00) years.
The biopsies were classified as nodular sclerosis in 88 (57.1%)
patients, mixed cellularity in 57 (37%), lymphocyte-rich classical
HD in two (1.3%), lymphocyte depleted in two (1.3%) and
undetermined HD in five (3.3%).
Immunohistochemistry
Cytoplasmic LMP1 immunostaining was positive in 46 (31.1%) of
147 cases. The IHC expression of MV antigens is shown in Table 2
and Figures 1 and 2. According to our definition of positivity, 82
(54.3%) cases were positive and 69 (45.7%) were negative for MV
antigens. Immunostaining was cytoplasmic. It was granular in
some cases, mainly with the L39/22 anti-NP antibody. Staining was
never noted in the cell membrane even with anti-HA antibodies.
Fixation in B5 gave better results than neutral formalin. We found
that a case that showed positivity for one of the HA antigens had a
90.2% chance of being positive for an NP antigen, but only 34.9%
of NP-positive HRS cells were also HA positive. All the NHL cases
studied were negative for MV antigens.
Figure 1 IHC studies for the NP-MV antigens (IHC with diaminobenzi-
dine,  430): (A) HD case, negative with the L39/22 anti-NP antibody. (B)
HD case positive with the L39/22 anti-NP antibody in HRS cells. (C)H D
case positive with the L39/61 anti-NP antibody in HRS cells.
Table 2 Immunohistochemical documentation of the expression of
various measles virus antigens in tumor cells
n Positive n (%) Negative n (%)
Nucleoprotein
H14 149 67 (45) 82 (55)
L39/22 130 80 (61.5) 50 (38.5)
L39/61 141 51 (36.2) 90 (63.8)
MNP (Chemicon) 56 30 (53.6) 26 (46.4)
HA
K83 81 25 (30.9) 56 (69.1)
L77 84 32 (38.1) 52 (61.9)
H2 (Chemicon) 23 14 (60.9) 9 (39.1)
HA¼haemagglutinin.
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Reverse transcriptase–polymerase chain reaction and nested PCR
were performed on frozen tissues from 16 HD cases and were
positive for HA-MV in three cases, positive for both HA-MV and
NP-MV in an additional case and negative for both HA-MV and
NP-MV in 12 cases. In all the positive cases and in 10 of the
negative cases, the housekeeping gene pp2Cb showed the presence
of good quality RNA.
Reverse transcriptase–polymerase chain reaction for HA-MV
was also performed on RNA extracted from paraffin sections in 12
additional cases in which no frozen tissue was available. It was
positive in three cases and negative in nine. As negative controls,
we used a case of HD that was negative for MV by IHC as well as
seven cases of various NHL ranging from small lymphocytic
lymphoma to diffuse large B-cell lymphoma. All these controls
were negative for HA-MV and NP-MV. The majority of the control
cases (85%) were positive for pp2Cb.
Southern blot analysis cDNA from the RT–PCR studies were
used. HA-MV was positive in four and negative in 11 cases. NP-
MV was positive in two and negative in 14 cases. The seven cases
of NHL were negative for MV (Figure 3).
Sequencing Cloning and sequencing were performed in three
cases that were positive for HA-MV and almost complete
homology with the control strain of the MV (GenBank accession
number – AF172985) was found (Figure 4).
In situ hybridisation (Figure 5)
NP-MV was positive in five and negative in 13 cases of HD. In
the positive cases, the signal was located in the cytoplasm of HRS
cells. In three additional cases, both N- and C-terminal NP-MV
were positive. HA-MV was positive in two and negative in five
cases. The two neuroblastoma cell lines were confirmed as positive
and negative controls. Two cases of HD negative for MV by IHC,
an uninvolved bone marrow biopsy from an HD patient and the
NHL cases studied, were all negative in the ISH studies.
Figure 2 IHC studies for other MV antigens (IHC with diaminobenzidine,  430): (A) HD case positive with the L77 anti-HA antibody in HRS cells. (B)
HD case positive with the H2 anti-HA antibody in HRS cells. (C) HD case positive with an anti-matrix antibody in HRS cells. (D) HD case positive with an
anti-phosphoprotein antibody in HRS cells.
PC 134 195253 236260 211 249 247 228 250 254 252 233 259235237NC
PC 134 195253 236260 211 249 247 228 250 254 252 233 259235237NC
A
B
CD
H
NP
H NP
PC 123456 7 123456 7 N C PC NC
Figure 3 Southern blot using cDNA products of an RT–PCR
performed to detect MV-RNAs: (A) and (C) were hybridised with probes
for HA-MV; (B) and (D) with probes for NP-MV. (A) and (B) show HD
cases (PC-positive control – the neuroblastoma cell line persistently
infected with MV; NC-negative control – the same cell line, not infected by
MV). (C) and (D) show NHL cases.
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The results of the different assays employed are compared in
Table 3. The rate of positivity was highest for IHC and lowest for
RT–PCR in the sample in which the comparison was made.
Clinicopathological correlations
As indicated above, the HRS cells in 54.3% of our 154 HD patients
showed positive immunostaining for MV antigens. Tumour cells
were positive for MV in significantly more female than male
patients (40 (64.5%) female and 42 (47.2%) male patients –
P¼0.036). Nodular sclerosis HD was more frequently associated
with MV than mixed cellularity HD (58 (68.2%) as compared with
21 (40.4%) – P¼0.0013). All possible combinations of immunos-
taining for MV and LMP were observed. When patients with
positive MV and negative LMP immunostaining (MVþ; LMP )
were studied for histologic type and compared with MV ; LMPþ
cases, the association of NS-HD with isolated MV positivity was
even more striking (P¼0.00008) (Table 4). The MVþ; LMP 
combination was also significantly associated with early Ann
Arbor stages (P¼0.023). It is worth noting that more than 35 of
the LMP  cases were also MV .
DISCUSSION
We have recently suggested that antigens and nucleic acids of the
MV may be present in the lymph nodes of HD patients
(Benharroch et al, 2003). We were aware of methodologic
limitations in our initial studies and could not exclude the
possibility that the MV may grow preferentially in the large
tumour B (HRS) cells of this disease. However, the IHC evidence
for the presence of the MV antigens, including several of the MV
proteins, was impressive. On the other hand, the yield of the RT–
PCR analysis was low. There are several possible explanations for
this finding, the most likely being a low MV-RNA content in the
HRS cells or the high content of RNAses in the eosinophils that are
usually numerous in HD tissues (Benharroch et al, 2003).
Considering a causal relationship between the MV and HD on
the basis of these findings would have been premature
(Benharroch et al, 2003), and it should be remembered that it
took decades to establish such a link between EBV and HD and
some still refute its validity (Harris, 1999). The presence of
persistent MV infection in tissues other than the central nervous
system is still questioned (Griffin, 2001). It is most probable that
only persistent infection would explain a malignant tumour
developing years following MV infection. Although MV is not
HD-134   GAGCTCAAACTCGCAGCCCTTTGTCACGGGGAAGATTCTATCACAATTCCCTATCAGGGA 60
HD-195   GAGCTCAAACTCGCAGCCCTTTGTCACGGGGAAGATTCTATCACAATTCCCTATCAGGGA 60
HD-26363   GAGCTCAAACTCGCAGCCCTTTGTCACGGGGAAGATTCTATCACAATTCCCTATCAGGGA 60
NB-CL-2716   --GCTCAAACTCGCAGCCCTTTGTCACGGGGAAGATTCTATCACAATTCCCTATCAGGGA 58
AF172985.    GAGCTCAAACTCGCAGCCCTTTGTCACGGGGAAGATTCTATCACAATTCCCTATCAGGGA 60
**********************************************************
HD-134   TCAGGGAAAGGTGTCAGCTTCCAGCTCGTCAAGCTAGGTGTCTGGAAATCCCCAACCGAC 120
HD-195   TCAGGGAAAGGTGTCAGCTTCCAGCTCGTCAAGCTAGGTGTCTGGAAATCCCCAACCGAC 120
HD-26363   TCAGGGAAAGGTGTCAGCTTCCAGCTCGTCAAGCTAGGTGTCTGGAAATCCCCAACCGAC 120
NB-CL-2716   TCAGGGAAAGGTGTCAGCTTCCAGCTCGTCAAGCTAGGTGTCTGGAAATCCCCAACCGAC 118
AF172985.    TCAGGGAAAGGTGTCAGCTTCCAGCTCGTCAAGCTAGGTGTCTGGAAATCCCCAACCGAC 120
************************************************************
HD-134   ATGCAATCCTGGGTCCCCTTATCAACGGATGATCCAGTGATAGACAGGCTTTACCTCTCA 180
HD-195   ATGCAATCCTGGGTCCCCTTATCAACGGATGATCCAGTGATAGACAGGCTTTACCTCTCA 180
HD-26363   ATGCAATCCTGGGTCCCCTTATCAAAGGATGATCCAGTGATAGACAGGCTTTACCTCTCA 180
NB-CL-2716   ATGCAATCCTGGGTCCCCTTATCAACGGATGATCCAGTGATAGACAGGCTTTACCTCTCA 178
AF172985.    ATGCAATCCTGGGTCCCCTTATCAACGGATGATCCAGTGATAGACAGGCTTTACCTCTCA 180
************************* **********************************
HD-134   TCTCACAGAGGTGTTATCGCTGACAACCAAGCAAAATGGGCTGTCCCGACAACACGAACA 240
HD-195   TCTCACAGAGGTGTTATCGCTGACAACCAAGCAAAATGGGCTGTCCCGACAACACGAACA 240
HD-26363   TCTCACAGAGGTGTTATCGCTGACAACCAAGCAAAATGGGCTGTCCCGACAACACGAACA 240
NB-CL-2716   TCTCACAGAGGTGTTATCGCTGACAATCAAGCAAAATGGGCTGTCCCGACAACACGAACA 238
AF172985.    TCTCACAGAGGTGTTATCGCTGACAATCAAGCAAAATGGGCTGTCCCGACAACACGAACA 240
************************** *********************************
HD-134   GATGACAAGTTGCTAATGGAGACATGCTTCCAACAGGCGTGTAAGGGTAAAATCCAAGCA 300
HD-195   GATGACAAGTTGCTAATGGAGACATGCTTCCAACAGGCGTGTAAGGGTAAAATCCAAGC- 299
HD-26363   GATGACAAGTTGCGAATGGAGACATGCTTCCAACAGGCGTGTAAGGGTAAAATCCAAGCA 300
NB-CL-2716   GATGACAAGTTGCGAATGGAGACATGCTTCCAACAGGCGTGTAAGGGTAAAATCCAAGCA 298
AF172985.    GATGACAAGTTGCGAATGGAGACATGCTTCCAACAGGCGTGTAAGGGTAAAATCCAAGCA 300
************* ********************************************* 
HD-134   CTCTGCGAGAATCCCGAGTGGGCACCATTGAAGGATAA 338
HD-195   CTCTGCGAGAATCCCGAGTGGGCACCATTGAAGGATAA 337
HD-26363   CTCTGCGAGAATCCCGAGTGGGCACCATTGAAGGATAA 338
NB-CL-2716   CTCTGCGAGAATCCCGAGTGGGCACCATTGAAGGATAA 336
AF172985.    CTCTGCGAGAATCCCGAGTGGGCACCATTGAAGGATAA 338
**************************************
Figure 4 Alignment of MV-HA cDNA sequences isolates from three HD patients. NB-CL-2716 is a neuroblastoma cell line persistently infected by the
Edmonston strain of MV. AF172985 is the GenBank accession number of the sequence of the Edmonston strain of the MV. Asterisks indicate single-
nucleotide differences in the sequence.
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epidemiological association not only between MV and brain
tumours but also with HD (Dickinson et al, 2002; Tyari et al, 2003).
We have now expanded our IHC study by using both
commercial and experimental antibodies to the NP, HA, M and
P antigens in a larger series of cases of HD. The specificity of some
of the antibodies used in this study was established by Western
blotting.
We feel that the results of the present study support our
previous findings on the expression of MV antigens in the HRS
cells in many cases of HD (Benharroch et al, 2003). Moreover, the
much more marked coexpression of HA-MV in cases positive for
NP-MV antigens than the coexpression of NP-MV in cases positive
with HA-MV antigens is consistent with the predominance of NP
antigens among the MV proteins (Griffin, 2001). The absence of
membrane expression of HA-MV antigens may be due to formalin
or B5 fixation. It is worth noting that Griffin (2001) described a
reduced expression of membranal HA-MV antigens in persistently
MV-infected cells.
The small proportion of positive cases with RT–PCR may be
due to the low content of MV-RNA in HD tissues because of the
low number of HRS cells in the lesions. We should have overcome
this difficulty by the use of nested RT–PCR but the intrinsic
lability of RNA, especially in archival material, but also in frozen
tissues, which had been stored at  701C for 6 months to 7 years,
represents a serious drawback. The possible effect of ribonucleases
in the eosinophils may also be responsible for the low yield of MV-
RNA by RT–PCR (Slifman et al, 1986; Norrback et al, 1998;
Hamalainen et al, 1999). These limitations probably reflect an
underestimate of the MV-RNA content of our biopsies.
We nevertheless detected MV-RNA in seven of 28 of our cases of
HD by RT–PCR. The Southern blot analysis showed MV-RNA in
only six of the seven cases, but this difference may be technical.
Sequencing, carried out in four cases positive for HA-MV
including one that was positive for NP- and HA-MV supported
the above findings and unequivocally confirmed the identity of the
virus. The presence of MV sequences was further established by
ISH demonstration of MV-RNA in 10 of 28 cases of HD. We have
thus demonstrated the presence of the MV in HD biopsies by
several independent techniques.
For the reasons discussed above, we were unable to demonstrate
an association between positivity of HD cases for MV antigens by
IHC and for MV-RNA by RT–PCR or by ISH. However, such an
association would depend on the ability of HRS cells to translate
Figure 5 ISH ( 430): (A) Positive control, the 2716 neuroblastoma cell line infected by MV. (B) HD case negative for MV by IHC. (C) HD case positive
for HA-MV RNA. (D) HD case positive for NP-MV RNA.
Table 3 Comparison of results obtained by three assays
NP-MV HA-MV
Positive/n (%) Positive/n (%)
RT-PCR 1/16 (6.25) 7/21 (33.3)
ISH 7/14 (50) 4/7 (57.1)
IHC 25/29 (86.2) 20/29 (68.9)
HA¼haemagglutinin; NP¼nucleoprotein; MV¼measles virus; RT–PCR¼reverse
transcriptase–polymerase chain reaction; ISH¼in situ hybridisation studies;
IHC¼immunohistochemical.
Table 4 Associations between the expression of MV and EBV (LMP) by
histological type of HD
Mixed cellularity (%) Nodular sclerosis (%)
MV+; LMP  11 (19.6) 45 (80.4)
MV ;L M P + 14 (66.7) 7 (33.3)
MV+; LMP+ 10 (47.6) 11 (52.4)
MV ;L M P   15 (42.9) 20 (57.1)
MV¼measles virus; EBV¼Epstein–Barr virus; LMP¼latent membrane protein;
HD¼Hodgkin’s disease.
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techniques, including the preservation of the available tissues.
Further studies are necessary to determine whether these
variations are of biological significance.
The finding of an association between the expression of MV
antigens and female gender and NS histological type should clearly
be regarded as preliminary and needs confirmation in a larger
cohort of HD patients. This finding does not seem consistent with
the apparent increase of incidence of the NS subset of HD in
female patients, which has been reported in some Western
countries in recent years (Liu et al, 2000). However, the full
impact of measles vaccination on the incidence of HD may only be
apparent after the complete eradication of measles. In Scandina-
vian countries, a significant reduction in the incidence of NS HD in
young adult females has, in fact, occurred (Merk et al, 1990; Foss-
Abrahamsen et al, 1997), and may perhaps be related to a more
stringent control of measles. On the other hand, in spite of the
prevailing measles vaccination policy, late exposure to MV occurs
in unvaccinated patients and in young adults with waning
immunity (Wood and Brunell, 1995). The reported decline in the
frequency of measles vaccination in the United Kingdom (Jansen
et al, 2003) would be counteractive to a decrease in the incidence
of HD. In addition, frequent asymptomatic measles infection has
been observed during outbreaks in highly immune individuals
(Sonoda et al, 2002).
Even though our clinicopathological findings are presented at a
very early stage, it seems clear that NS-HD is preferentially
associated with the MVþ; LMP (EBV)  phenotype. However, in
more than 20% of our cases, the two viruses are expressed in
consecutive sections in each case. Since immunosuppression of
limited duration is well documented in measles, a synergistic
interaction of MV with EBV may be relevant in terms of
pathogenesis in these 20 cases.
In conclusion, we have documented further evidence for the
presence of MV antigens and the MV genome in tissue biopsies
from untreated HD patients. Our findings are worth noting in view
of the recent reports from the United Kingdom, suggesting an
epidemiologic relationship between prenatal and perinatal ex-
posure to MV and the occurrence of brain tumours and HD.
Further investigations are needed to confirm our findings and to
establish their possible pathogenetic significance.
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